letrozole has been researched along with Stunted Growth in 22 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Letrozole was superior to placebo [mean difference (MD) 4." | 2.82 | Efficacy and Safety of Letrozole in the Management of Constitutional Delay in Growth and Puberty: A Systematic Review and Meta-analysis ( Dutta, D; Sharma, M; Singla, R; Surana, V, 2022) |
| "Letrozole was more potent in hormonal manipulation than anastrozole." | 2.79 | Letrozole vs anastrozole for height augmentation in short pubertal males: first year data. ( Kumar, RB; Neely, EK; Payne, SL; Ranadive, SA; Suchet, DI, 2014) |
| "In letrozole-treated boys, the concentrations of the bone resorption marker urine aminoterminal telopeptide of type I collagen initially increased and thereafter slowly declined while the concentrations of the bone formation markers serum aminoterminal propeptide of type I collagen and serum alkaline phosphatase remained unchanged or slightly increased, respectively." | 2.74 | Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. ( Dunkel, L; Hero, M; Kröger, H; Mäkitie, O; Nousiainen, E; Toiviainen-Salo, S, 2009) |
| "Letrozole treatment caused sustained reduction in bone strength and alteration in skeletal geometry, lowering of IGF1 levels, inhibition of growth resulting in significantly lower weight and length of treated animals and development of focal prostatic hyperplasia." | 1.36 | Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia. ( Azar, WJ; Bajpai, A; McPherson, SJ; Risbridger, GP; Russo, VC; Simm, PJ; Wark, JD; Werther, GA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 11 (50.00) | 24.3611 |
| 2020's | 4 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Dutta, D | 1 |
| Singla, R | 1 |
| Surana, V | 1 |
| Sharma, M | 1 |
| Likki, SR | 1 |
| Allen, HF | 1 |
| Knee, A | 1 |
| Tonyushkina, KN | 1 |
| Cui, YP | 1 |
| Wang, XL | 1 |
| Rohani, F | 1 |
| Asadi, R | 1 |
| Mirboluk, AA | 1 |
| Soheilipour, F | 1 |
| Kohva, E | 1 |
| Varimo, T | 3 |
| Huopio, H | 1 |
| Tenhola, S | 1 |
| Voutilainen, R | 1 |
| Toppari, J | 1 |
| Miettinen, PJ | 3 |
| Vaaralahti, K | 4 |
| Viinamäki, J | 1 |
| Backman, JT | 1 |
| Hero, M | 8 |
| Raivio, T | 4 |
| Wang, Y | 1 |
| Neely, EK | 1 |
| Kumar, RB | 1 |
| Payne, SL | 1 |
| Ranadive, SA | 1 |
| Suchet, DI | 1 |
| Dunkel, L | 7 |
| Mäkitie, O | 2 |
| Kröger, H | 1 |
| Nousiainen, E | 1 |
| Toiviainen-Salo, S | 2 |
| Kumar, KV | 1 |
| Jayaraman, M | 1 |
| Verma, A | 1 |
| Modi, KD | 1 |
| Wickman, S | 1 |
| Maury, S | 1 |
| Luotoniemi, E | 1 |
| Service, E | 1 |
| Salehpour, S | 1 |
| Alipour, P | 1 |
| Razzaghy-Azar, M | 1 |
| Ardeshirpour, L | 1 |
| Shamshiri, A | 1 |
| Monfared, MF | 1 |
| Gharib, A | 1 |
| Bajpai, A | 1 |
| Simm, PJ | 1 |
| McPherson, SJ | 1 |
| Russo, VC | 1 |
| Azar, WJ | 1 |
| Wark, JD | 1 |
| Risbridger, GP | 1 |
| Werther, GA | 1 |
| Tommiska, J | 1 |
| Laitinen, EM | 1 |
| Sipilä, I | 1 |
| Puhakka, L | 1 |
| Krebs, A | 1 |
| Moske-Eick, O | 1 |
| Doerfer, J | 1 |
| Roemer-Pergher, C | 1 |
| van der Werf-Grohmann, N | 1 |
| Schwab, KO | 1 |
| Zhou, P | 1 |
| Shah, B | 1 |
| Prasad, K | 1 |
| David, R | 1 |
| Karmazin, A | 1 |
| Moore, WV | 2 |
| Popovic, J | 2 |
| Jacobson, JD | 2 |
| Norjavaara, E | 1 |
| Cernich, J | 1 |
| Chagin, AS | 1 |
| Sävendahl, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment[NCT01797718] | Phase 2/Phase 3 | 35 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Randomization to Letrozole vs. Anastrozole in Short Pubertal Males[NCT02137538] | Phase 4 | 79 participants (Actual) | Interventional | 2009-11-18 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Heights will be obtained by physical exam every 6 months during treatment. Skeletal maturation will be assessed from an x-ray by the method of Greulich and Pyle at baseline and every 12 months until the end of treatment.~Predicted adult height will be calculated at baseline and at the end of treatment based upon measured height and skeletal maturation (bone age)." (NCT02137538)
Timeframe: Year 3
| Intervention | cm (Mean) |
|---|---|
| Letrozole | 167.8 |
| Anastrozole | 169.4 |
(NCT02137538)
Timeframe: Baseline, year 3
| Intervention | ng/dL (Mean) | |
|---|---|---|
| Baseline | Year 3 | |
| Anastrozole | 37.4 | 77.9 |
| Letrozole | 35.3 | 79.9 |
(NCT02137538)
Timeframe: Baseline, year 3
| Intervention | ng/dL (Mean) | |
|---|---|---|
| Baseline | Year 3 | |
| Anastrozole | 19.1 | 44.1 |
| Letrozole | 22.5 | 65.0 |
(NCT02137538)
Timeframe: Baseline, year 3
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline | Year 3 | |
| Anastrozole | 4.7 | 6.2 |
| Letrozole | 4.9 | 2.7 |
(NCT02137538)
Timeframe: Baseline, year 3
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline | Year 3 | |
| Anastrozole | 8.0 | 3.5 |
| Letrozole | 8.7 | 2.7 |
(NCT02137538)
Timeframe: Baseline, year 3
| Intervention | mIU/mL (Mean) | |
|---|---|---|
| Baseline | Year 3 | |
| Anastrozole | 2.5 | 4.5 |
| Letrozole | 3.3 | 6.6 |
(NCT02137538)
Timeframe: Baseline, year 3
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline | Year 3 | |
| Anastrozole | 217.0 | 262.1 |
| Letrozole | 203.4 | 257.6 |
(NCT02137538)
Timeframe: Baseline, year 3
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Baseline | Year 3 | |
| Anastrozole | 306.9 | 298.7 |
| Letrozole | 306.2 | 226.1 |
(NCT02137538)
Timeframe: Baseline, year 3
| Intervention | mIU/mL (Mean) | |
|---|---|---|
| Baseline | Year 3 | |
| Anastrozole | 1.8 | 3.4 |
| Letrozole | 2.3 | 4.7 |
(NCT02137538)
Timeframe: 3 years
| Intervention | events (Number) | |
|---|---|---|
| Acne | Fracture | |
| Anastrozole | 3 | 5 |
| Letrozole | 3 | 3 |
(NCT02137538)
Timeframe: Baseline, year 3
| Intervention | ng/dL (Mean) | |
|---|---|---|
| Baseline | Year 3 | |
| Anastrozole | 162.1 | 680.1 |
| Letrozole | 213.1 | 882.3 |
2 reviews available for letrozole and Stunted Growth
| Article | Year |
|---|---|
Efficacy and Safety of Letrozole in the Management of Constitutional Delay in Growth and Puberty: A Systematic Review and Meta-analysis
Topics: Body Height; Child; Growth Disorders; Humans; Letrozole; Luteinizing Hormone; Puberty; Puberty, Dela | 2022 |
Use of aromatase inhibitors in children with short stature.
Topics: Adult; Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Body Height; Child; Estrogens; Fema | 2004 |
11 trials available for letrozole and Stunted Growth
| Article | Year |
|---|---|
Anti-Müllerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone.
Topics: Adolescent; Anti-Mullerian Hormone; Biomarkers; Child; Female; Finland; Growth Disorders; Humans; Hy | 2020 |
Circulating miR-30b levels increase during male puberty.
Topics: Adolescent; Drug Therapy, Combination; Gonads; Growth Disorders; Hormone Replacement Therapy; Humans | 2021 |
Letrozole vs anastrozole for height augmentation in short pubertal males: first year data.
Topics: Adolescent; Anastrozole; Aromatase Inhibitors; Body Height; Child; Estradiol; Growth Disorders; Huma | 2014 |
Circulating makorin ring finger protein 3 levels decline in boys before the clinical onset of puberty.
Topics: Adolescent; Aromatase Inhibitors; Child; Double-Blind Method; Growth Disorders; Humans; Letrozole; M | 2016 |
Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature.
Topics: Absorptiometry, Photon; Adolescent; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Develop | 2009 |
Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty.
Topics: Adolescent; Aromatase Inhibitors; Child; Growth Disorders; Humans; Letrozole; Magnetic Resonance Ima | 2010 |
Cognitive effects of aromatase inhibitor therapy in peripubertal boys.
Topics: Adolescent; Aromatase Inhibitors; Child; Cognition; Double-Blind Method; Growth Disorders; Humans; L | 2010 |
A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature.
Topics: Adolescent; Androgens; Aromatase Inhibitors; Body Height; Bone Density; Cholesterol; Double-Blind Me | 2010 |
Circulating antimüllerian hormone levels in boys decline during early puberty and correlate with inhibin B.
Topics: Adolescent; Anti-Mullerian Hormone; Aromatase Inhibitors; Biomarkers; Child; Cross-Sectional Studies | 2012 |
The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function.
Topics: Adolescent; Adrenal Glands; Adrenocorticotropic Hormone; Aromatase Inhibitors; Body Height; Bone and | 2005 |
Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial.
Topics: Absorptiometry, Photon; Adolescent; Aromatase Inhibitors; Body Height; Bone Density; Child; Double-B | 2005 |
9 other studies available for letrozole and Stunted Growth
| Article | Year |
|---|---|
Use of letrozole to augment height outcome in pubertal boys: a retrospective chart review.
Topics: Adult; Body Height; Growth Disorders; Growth Hormone; Human Growth Hormone; Humans; Letrozole; Male; | 2022 |
[Clinical effect of letrozole in treatment of idiopathic short stature in adolescent boys].
Topics: Adolescent; Body Height; Dwarfism; Growth Disorders; Human Growth Hormone; Humans; Letrozole; Male; | 2019 |
Letrozole Effect on Final Height of Patients with Constitutional Delay of Growth and Puberty.
Topics: Adolescent; Aromatase Inhibitors; Body Height; Case-Control Studies; Follow-Up Studies; Growth Disor | 2019 |
Letrozole as a booster therapy in growth hormone deficiency.
Topics: Adolescent; Aromatase Inhibitors; Growth Disorders; Growth Hormone; Humans; Letrozole; Male; Nitrile | 2009 |
Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia.
Topics: Animals; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Development; Child; Growth Disorde | 2010 |
Off-label use of aromatase inhibitors to promote taller stature: is it safe.
Topics: Adolescent; Aromatase Inhibitors; Body Height; Growth Disorders; Humans; Letrozole; Male; Nitriles; | 2010 |
Marked increase of final height by long-term aromatase inhibition in a boy with idiopathic short stature.
Topics: Adolescent; Aromatase; Aromatase Inhibitors; Body Height; Bone and Bones; Growth Disorders; Humans; | 2012 |
Letrozole significantly improves growth potential in a pubertal boy with growth hormone deficiency.
Topics: Adolescent; Aromatase Inhibitors; Biomarkers; Bone Density; Drug Therapy, Combination; Growth Disord | 2005 |
Oestrogen receptors and linear bone growth.
Topics: Animals; Anthropometry; Aromatase Inhibitors; Bone Development; Child; Estrogen Receptor beta; Estro | 2007 |